OncoMatch/Clinical Trials/NCT02917083
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Is NCT02917083 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for hodgkin's lymphoma.
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells. The gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown. Several studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called "lymphodepletion" CD30.CAR T cells have previously been studied in lymphoma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD30 positive tumor
CD30 positive tumor as assayed in a CLIA certified pathology laboratory
Prior therapy
Cannot have received: investigational agent
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks.
Cannot have received: anti-CD30 antibody-based therapy
Received anti-CD30 antibody-based therapy within the previous 4 weeks.
Lab requirements
Blood counts
Hgb ≥ 7.0 (may be a transfused value)
Kidney function
Estimated GFR > 70 mL/min
Liver function
Bilirubin 1.5 times or less than the upper limit of normal; AST 3 times or less than the upper limit of normal
Cardiac function
EKG shows no significant arrhythmias; Symptomatic cardiac disease (NYHA Class III or IV disease) excluded
Bilirubin 1.5 times or less than the upper limit of normal. AST 3 times or less than the upper limit of normal. Estimated GFR > 70 mL/min. Hgb ≥ 7.0 (may be a transfused value). EKG shows no significant arrhythmias. Symptomatic cardiac disease (NYHA Class III or IV disease) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist Hospital · Houston, Texas
- Texas Children's Hospital · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify